This protocol addresses first-line systemic treatment for patients with newly diagnosed pleural mesothelioma whose tumour has nonepithelioid histology and who have a medical contraindication to immunotherapy, with no prior systemic therapy.
The patient presents with newly diagnosed pleural mesothelioma confirmed as nonepithelioid histologic subtype. Immunotherapy cannot be used due to a medical contraindication, and no prior systemic therapy has been given. This combination of factors defines a distinct first-line treatment population for which a specific approach is supported by current evidence.
Evidence supports adding pegargiminase to platinum-based chemotherapy as a first-line option in this setting. The complete regimen — including all agents involved, their sequencing, and administration details — is available in the full structured protocol.
DOI: 10.1200/JCO-24-02425
In patients with nonepithelioid histology who have not received any prior systemic therapy and are not candidates for immunotherapy, the addition of pegargiminase to pemetrexed plus platinum chemotherapy may be offered as a treatment option.
View source ↗